Cytokinetics' Myqorzo Approved for Heart Condition
Update: 2025-12-21
Description
Cytokinetics Myqorzo, a new drug for heart condition, approved by FDA, positions it as rival to Bristol Myers Squibbs Camzyos, with fewer restrictions and potential for wider use, marking a fresh start for Cytokinetics and expanded options for heart patients.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
